Vivo Capital and AACR

Selected healthcare news for the capital firm - Vivo Capital, and the healthcare topic - AACR. We have a small number of shared news items for this connection to-date. Based on the volume of shared news, it's source, placement and other factors, this connection has a medium score.  Vivo Capital shares healthcare news with Preventice, Preventice Solutions, Biotech, OrbiMed and dozens of others. AACR shares news with American Association for Cancer Research, Oncology, Clinical Data, Food and Drug Administration, Verastem Oncology and hundreds of others.

Selected Headlines

Date Headline (link) Source Relevant Snippet
3/11/2020 Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results | Business Wire Business Wire ... as possible. Data from the Phase 1 combination study were submitted for presentation to the American Association for Cancer Research (AACR) 2020 Annual Meeting. The AACR recently announced that it was terminating the April 2020 ... common stock to certain institutional investors, including RA Capital Management, Vivo Capital, Venrock Healthcare Capital Partners, Farallon Capital Management, Acuta Capital, EcoR1 Capital LLC, Avidity Partners and Logos Capital at a price of $2.15 per ...
3/11/2020 Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results Business Wire ... soon as possible.Data from the Phase 1 combination study were submitted for presentation to the American Association for Cancer Research (AACR) 2020 Annual Meeting. The AACR recently announced that it was terminating the April 2020 ... common stock to certain institutional investors, including RA Capital Management, Vivo Capital, Venrock Healthcare Capital Partners, Farallon Capital Management, Acuta Capital, EcoR1 Capital LLC, Avidity Partners and Logos Capital at a price of $2.15 per ...
11/11/2019 Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors FierceBiotech ... Vivo Capital, Nan Fung Life Sciences and Pivotal bioVenture Partners. At the American Association for Cancer Research (AACR) conference in April, Bolt released preclinical data showing that its IASC could kill human HER2-positive tumor models that had previously been treated with Herceptin, the pioneering Genentech drug that is now the standard of care for these stubborn cancers. In animal trials also presented at the AACR conference, Bolt’s therapy was ...
10/8/2019 Bolt Biotherapeutics Announces Scientific Advisory Board with the Appointment of Drs. Larry Fong, Roy Herbst and Bruce Roth PR Newswire ... program committees and editorial boards for the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR). He is co-director of the Parker Institute for Cancer Immunotherapy at UCSF and ... by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com where you will find complete biographies of Bolt's SAB ...